somapacitan: Clinical Trials

21 trials of somapacitan, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

13 completed, 4 active not recruiting, 3 enrolling by invitation, 1 recruiting. 7 Phase 1, 7 Phase 3, 2 Phase 2, 1 Early Phase 1.

By phase and status

PhaseTrialsStatus
Phase 17Completed 7
Phase 37Completed 5, Active not recruiting 2
Phase 22Active not recruiting 1, Completed 1
Early Phase 11Recruiting 1

Follow somapacitan: new trials by email Literature Review of somapacitan trials Research Report on somapacitan

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Follow Paediatric Participants With Growth Hormone Deficiency Treated With Somapacitan for Long Term Safety Information and Clinical Parameters
Somapacitan - Growth Hormone Deficiency, Neoplasms
Enrolling by invitationNovo Nordisk A/S5002024-12-132026-04-06
Growth Hormone for the Treatment of Gastroparesis
Growth Hormone - Gastroparesis
Early Phase 1RecruitingMayo Clinic102024-10-222026-04-16
Special Use-results Surveillance on Long Term Use of Sogroya® in Children With Short Stature Due to Growth Hormone Deficiency Where Epiphysial Discs Are Not Closed
Somapacitan - Growth Hormone Deficiency in Children
Enrolling by invitationNovo Nordisk A/S2002023-10-042026-04-29
A Study to Follow Patients With Adult Growth Hormone Deficiency (AGHD) Treated With Sogroya® for Long Term Safety Information
Somapacitan - Adult Growth Hormone Deficiency
Enrolling by invitationNovo Nordisk A/S4002023-02-032026-06-12
A Research Study Looking at How Safe Somapacitan is and How Well it Works in Children Who Need Help to Grow - REAL 9
Somapacitan - SGA, Turner Syndrome
Phase 3Active not recruitingNovo Nordisk A/S472023-02-012026-08-13
A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow
Somapacitan, Norditropin® - SGA, Turner Syndrome, Noonan Syndrome, ISS
Phase 3Active not recruitingNovo Nordisk A/S4122022-08-102026-06-12
Post-Marketing Surveillance (Special Use-results Surveillance on Long-term Use) With Sogroya®
Somapacitan - Adult Growth Hormone Deficiency
Active not recruitingNovo Nordisk A/S2002022-02-032026-04-13
A Research Study in Chinese Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day.
somapacitan, Norditropin® - Growth Hormone Deficiency in Children
Phase 3CompletedNovo Nordisk A/S1102021-07-222026-01-06
A Research Study in Children Born Small and Who Stayed Small. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day
Somapacitan, Norditropin® - Short Stature Children Born Small for Gestational Age (SGA)
Phase 2Active not recruitingNovo Nordisk A/S622019-07-042026-10-06
A Research Study in Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day (REAL4)
Somapacitan, Norditropin® - Growth Hormone Deficiency in Children
Phase 3CompletedNovo Nordisk A/S2002019-05-202026-10-22
A Study to Compare the Uptake Into the Blood of Two Strengths of Somapacitan After Injection Under the Skin in Healthy Subjects
somapacitan - Healthy Volunteers, Growth Hormone Deficiency
Phase 1CompletedNovo Nordisk A/S332019-03-292019-08-06
Investigation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Doses of Somapacitan in Subjects With Mild and Moderate Degrees of Hepatic Impairment Compared to Subjects With Normal Hepatic Function.
Somapacitan - Growth Hormone Disorder, Adult Growth Hormone Deficiency
Phase 1CompletedNovo Nordisk A/S342017-08-162019-05-24
Investigation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Doses of Somapacitan in Subjects With Various Degrees of Impaired Renal Function Compared to Subjects With Normal Renal Function
Somapacitan - Growth Hormone Disorder, Adult Growth Hormone Deficiency
Phase 1CompletedNovo Nordisk A/S442017-06-202020-04-17
A Trial to Evaluate the Safety of Once Weekly Dosing of Somapacitan (NNC0195-0092) and Daily Norditropin® FlexPro® for 52 Weeks in Previously Human Growth Hormone Treated Japanese Adults With Growth Hormone Deficiency
somapacitan, Norditropin - Growth Hormone Disorder, Adult Growth Hormone Deficiency
Phase 3CompletedNovo Nordisk A/S622017-03-032020-11-23
A Trial Investigating the Absorption, Metabolism and Excretion of Somapacitan After Single Dosing in Healthy Male Subjects
somapacitan - Healthy
Phase 1CompletedNovo Nordisk A/S72016-11-012017-06-07
Investigating Efficacy and Safety of Once-weekly NNC0195-0092 Treatment Compared to Daily Growth Hormone Treatment (Norditropin® FlexPro®) in Growth Hormone Treatment naïve Pre-pubertal Children With Growth Hormone Deficiency
somapacitan, Norditropin® FlexPro® pen - Growth Hormone Disorder, Growth Hormone Deficiency in Children
Phase 2CompletedNovo Nordisk A/S762016-03-312026-01-16
A Trial to Compare the Safety of Once Weekly Dosing of Somapacitan With Daily Norditropin® FlexPro® for 26 Weeks in Previously Human Growth Hormone Treated Adults With Growth Hormone Deficiency
somapacitan, somatropin - Adult Growth Hormone Deficiency, Growth Hormone Disorder
Phase 3CompletedNovo Nordisk A/S922015-02-122020-07-09
Trial to Compare the Efficacy and Safety of NNC0195-0092 (Somapacitan) With Placebo and Norditropin® FlexPro® (Somatropin) in Adults With Growth Hormone Deficiency.
somapacitan, somatropin, placebo - Growth Hormone Disorder, Adult Growth Hormone Deficiency
Phase 3CompletedNovo Nordisk A/S3012014-10-312020-11-23
A Trial Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose of Long-acting Growth Hormone (Somapacitan) Compared to Daily Dosing of Norditropin® SimpleXx® in Children With Growth Hormone Deficiency
somapacitan, somatropin - Growth Hormone Disorder, Growth Hormone Deficiency in Children
Phase 1CompletedNovo Nordisk A/S322013-12-162020-12-24
A Trial Investigating the Safety, Tolerability, Availability and Distribution in the Body of Once-weekly Long-acting Growth Hormone (Somapacitan) Compared to Once Daily Norditropin NordiFlex® in Adults With Growth Hormone Deficiency
somapacitan, Norditropin NordiFlex® - Growth Hormone Disorder, Adult Growth Hormone Deficiency
Phase 1CompletedNovo Nordisk A/S352012-10-122020-12-24

Showing 20 of 21. Sign in to see all of them.

Conditions studied

Dwarfism, Pituitary (11)  ·  Noonan Syndrome (2)  ·  Turner Syndrome (2)  ·  Diabetes Mellitus, Type 2 (1)  ·  Gastroparesis (1)  ·  Neoplasms (1)

Sponsors

Novo Nordisk A/S (20)  ·  Mayo Clinic (1)

Countries

Japan (10)  ·  Germany (9)  ·  United States (8)  ·  France (7)  ·  Israel (6)  ·  United Kingdom (6)  ·  Austria (5)  ·  India (5)  ·  Poland (5)  ·  Slovenia (5)  ·  Spain (5)  ·  Sweden (5)  ·  Canada (4)  ·  Denmark (4)  ·  Latvia (4)

Top investigators

Tisha Lunsford (1)

Results publications

PMID 29671202, PMID 36380045, PMID 33754315, PMID 33864240, PMID 25013997, PMID 26727076, PMID 28656605, PMID 31917835, PMID 32022863, PMID 32603494, PMID 34601071, PMID 34964458, PMID 36062966, PMID 36995872, PMID 37406251, PMID 38066644, PMID 38368603, PMID 38969919, PMID 39991735, PMID 40400262, PMID 41614610, PMID 41712606, PMID 41774755, PMID 42369274

NIH funding

2016 (3), 2018 (3), 2014 (1), 2015 (1)